MD Magazine (7/18, Walter) reports that even though antipsychotic medications “are considered the preferred treatment for schizophrenia, it is unclear which agent should ultimately be used to treat the disorder.” Now, German researchers “are hoping to provide a baseline guide outlining the risks and rewards after completing a network meta-analysis of placebo-controlled and head-to-head randomized controlled trials, comparing 32 antipsychotics including clozapine, levomepromazine, amisulpride, brexpiprazole, flupentixol, and sulpiride.” The review revealed that “there are some efficacy differences between antipsychotics, but most of them are gradual rather than discrete,” whereas “differences in side-effects are more marked.” The findings of the 402-study, 53,463-participant review were published online July 11 in The Lancet.
Related Links:
— “Study Distinguishes Schizophrenia Drug Effects Among Patients, “Kenny Walter, MD Magazine, July 18, 2019